The COPD Biomarker Qualification Consortium (CBQC)

References

• Kaitin KI, DiMasi JA. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000–2009. Clin Pharmacol Therapeut 2011; 89:183–188.
   PubMed Web of Science ®Google Scholar
• Woodcock J, Woosley R. The FDA critical path initiative and its influence on new drug development. Annu Rev Med 2008; 59:1–12.
   PubMed Web of Science ®Google Scholar
• FDA. Guidance for Industry Qualification Process for Drug Development Tools. 2010.
   Google Scholar
• FDA. Strategic Priorities: Cross-Cutting Strategic Priorities. http://www.fda.gov/aboutFDA/Reportsmanualsforms/Reports/ucm246737.htm
   Google Scholar
• Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175:250–255.
   PubMed Web of Science ®Google Scholar
• Dahl M, Tybjaerg-Hansen A, Vestbo J, Lange P, Nordestgaard BG. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:1008–1111.
   PubMed Web of Science ®Google Scholar
• Siva R, Green RH, Brightling CE, Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J 2007;29:906–13.
   PubMed Web of Science ®Google Scholar
• Hurst JR, Donaldson GC, Perera WR, Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174:867–74.
   PubMed Web of Science ®Google Scholar
• Bozinovski S, Hutchinson A, Thompson M, Serum amyloid a is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177:269–78.
   PubMed Web of Science ®Google Scholar
• Lomas DA, Silverman EK, Edwards LD, Miller BE, Coxson HO, Tal-Singer R. Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort. Thorax 2008; 63:1058–63.
   PubMed Web of Science ®Google Scholar
• Lomas DA, Silverman EK, Edwards LD, Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur Respir J 2009; 34:95–102.
   PubMed Web of Science ®Google Scholar
• Sin DD, Man SF, Marciniuk DD, The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177:1207–1214.
   PubMed Web of Science ®Google Scholar
• Sin DD, Vestbo J. Biomarkers in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2009; 6:543–545.
   PubMedGoogle Scholar
• Danesh J, Lewington S, Thompson SG, Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005; 294:1799–1809.
   PubMed Web of Science ®Google Scholar
• Barnes NC, Pavord ID, Maden C, Gomez E, Keene O, Tal-Singer R. Evaluation of an oral p38 mitogen activated protein kinase (MAPK inhibitor) SB-681323 in COPD. Eru Resp J 2009; 34(sup):544s.
   Google Scholar
• Lomas DA, Lipson DA, Miller BE, An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease. J Clin Pharmacol. 2012; 52:416–424.
   PubMed Web of Science ®Google Scholar
• Agusti A, Calverley PM, Celli B, Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010; 11:122.
   PubMed Web of Science ®Google Scholar
• Bergin C, Muller N, Nichols DM, The diagnosis of emphysema. A computed tomographic-pathologic correlation. Am Rev Respir Dis 1986; 133:541–546.
   PubMed Web of Science ®Google Scholar
• Muller NL, Staples CA, Miller RR, Abboud RT. “Density mask”. An objective method to quantitate emphysema using computed tomography. Chest 1988; 94:782–787.
   PubMed Web of Science ®Google Scholar
• Gevenois PA, De Vuyst P, Sy M, Pulmonary emphysema: quantitative CT during expiration. Radiology 1996; 199:825–829.
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Nasuhara Y, Onodera Y, Airflow limitation and airway dimensions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173:1309–1315.
   PubMed Web of Science ®Google Scholar
• Patel BD, Coxson HO, Pillai SG, Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 178:500–505.
   PubMed Web of Science ®Google Scholar
• Dirksen A, Piitulainen E, Parr DG, Exploring the role of CT densitometry: A randomised study of augmentation therapy in alpha-1 antitrypsin deficiency. Euro Respir J 2009; 33:1345–1353.
   PubMed Web of Science ®Google Scholar
• Dirksen A, Dijkman JH, Madsen F, A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999; 160:1468–1472.
   PubMed Web of Science ®Google Scholar
• Fishman A, Martinez F, Naunheim K, A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348:2059–2073.
   PubMed Web of Science ®Google Scholar
• Cote CG, Pinto-Plata V, Kasprzyk K, Dordelly LJ, Celli BR. The 6-min walk distance, peak oxygen uptake, and mortality in COPD. Chest 2007; 132:1778–1785.
   PubMed Web of Science ®Google Scholar
• Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med 2003; 167:544–549.
   PubMed Web of Science ®Google Scholar
• Spruit MA, Polkey MI, Celli B, Predicting outcomes from 6-minute walk distance in chronic obstructive pulmonary disease. J Am Med Dir Assoc 2012; 13:291–297.
   PubMed Web of Science ®Google Scholar
• Celli BR, Cote CG, Marin JM, The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350:1005–1012.
   PubMed Web of Science ®Google Scholar
• Gremeaux V, Troisgros O, Benaim S, Determining the minimal clinically important difference for the six-minute walk test and the 200-meter fast-walk test during cardiac rehabilitation program in coronary artery disease patients after acute coronary syndrome. Arch Phys Med Rehabil 2011; 92:611–619.
   PubMed Web of Science ®Google Scholar
• du Bois RM, Weycker D, Albera C, Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 2011; 183:1231–1237.
   PubMed Web of Science ®Google Scholar
• Gabler NB, French B, Strom BL, Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation 2012; 126:349–356.
   PubMed Web of Science ®Google Scholar
• Seymour JM, Spruit MA, Hopkinson NS, et al. The prevalence of quadriceps weakness in COPD and the relationship with disease severity. Eur Respir J 2010; 36:81–88.
   PubMed Web of Science ®Google Scholar
• Waschki B, Kirsten A, Holz O, Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest 2011; 140:331–342.
   PubMed Web of Science ®Google Scholar
• Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink R. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 171:972–977.
   PubMed Web of Science ®Google Scholar
• Waschki B, Spruit MA, Watz H, Physical activity monitoring in COPD: Compliance and associations with clinical characteristics in a multicenter study. Respir Med 2012; 106:522–530.
   PubMed Web of Science ®Google Scholar
• Luisetti M, Ma S, Iadarola P, Desmosine as a biomarker of elastin degradation in COPD: current status and future directions. Eur Respir J 2008; 32:1146–1157.
   PubMed Web of Science ®Google Scholar
• Turino GM, Ma S, Lin YY, Cantor JO, Luisetti M. Matrix elastin: a promising biomarker for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011; 184:637–641.
   PubMed Web of Science ®Google Scholar
• Chrzanowski P, Keller S, Cerreta J. Elastin content of normal and emphysematous lung parenchyma. Am J Med 1988; 69:351–359.
   Google Scholar
• Wright RR. Elastic tissue of normal and emphysematous lungs: a tridimensional histological study. Am J Pathol 1961; 39:355–363.
   PubMed Web of Science ®Google Scholar
• Ma S, Lieberman S, Turino GM, Lin YY. The detection and quantitation of free desmosine and isodesmosine in human urine and their peptide-bound forms in sputum. Proc Natl Acad Sci USA 2003; 100:12941–12943.
   PubMed Web of Science ®Google Scholar
• Ma S, Turino GM, Lin YY. Quantitation of desmosine and isodesmosine in urine, plasma, and sputum by LC-MS/MS as biomarkers for elastin degradation. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879:1893–1898.
   PubMed Web of Science ®Google Scholar
• Ma S, Lin YY, Turino GM. Measurements of desmosine and isodesmosine by mass spectrometry in COPD. Chest 2007; 131:1363–1371.
   PubMed Web of Science ®Google Scholar
• Fregonese L, Ferrari F, Funagalli M, Luisetti M, Stolk J, Iadarola P. Long-term variability of desmosine/isodesmosine as biomarker in alpha-1-antitrypsin deficiency-related COPD. J COPD 2011; 3:229–333.
   Google Scholar
• Lindberg CA, Engstrom G, de Verdier MG, Total desmosines in plasma and urine correlate with lung function. Eur Respir J 2012; 39:839–845.
   PubMed Web of Science ®Google Scholar
• Ma S, Lin YY, Tartell L, Turino GM. The effect of tiotropium therapy on markers of elastin degradation in COPD. Respir Res 2009; 10:12.
   PubMed Web of Science ®Google Scholar
• Montuschi P. Analysis of exhaled breath condensate in respiratory medicine: methodological aspects and potential clinical applications. Ther Adv Respir Dis 2007; 1:5–23.
   PubMedGoogle Scholar
• Borrill ZL, Roy K, Singh D. Exhaled breath condensate biomarkers in COPD. Eur Respir J 2008; 32:472–486.
   PubMed Web of Science ®Google Scholar
• Effros RM, Casaburi R, Su J, The effects of volatile salivary acids and bases on exhaled breath condensate pH. Am J Respir Crit Care Med 2006; 173:386–392.
   PubMed Web of Science ®Google Scholar
• Effros RM, Casaburi R, Porszasz J, Rehan V. Why conventional exhaled breath condensate pH studies cannot provide reliable estimates of airway acidification. Chest 2011; 140:1099.
   PubMed Web of Science ®Google Scholar